Neurimmune AG

Identification of novel therapeutics for the treatment of neurodegenerative disorders

Illnesses such as Alzheimer’s and Parkinson’s disease remain as yet incurable. Neurimmune plans to change that by taking an unusual approach. This startup has not investigated the factors that lead to illnesses but rather has focused on those that keep us healthy. The company is applying this knowledge to identify novel therapeutics.
www.neurimmune.com

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No milestones

No Jobs

No videos and documents

TOP 100 Swiss Startup Award

The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.

Website

CTI Start-up Label

CTI Start-up enables entrepreneurs to realize their innovative idea professionally.

In a process of three phases, over forty experienced coaches guide start-up companies on their way to enter the market successfully and attract financing. At the end of the coaching process, the most promising start-up companies have the opportunity to receive the prestigious CTI Start-up ’Label’. In addition, the companies benefit from the wide CTI Start-up network of industry experts, experienced entrepreneurs, business angels, venture capitalists and has access to foundations such as de Vigier, STI, FIT, Gebert, Rüf, etc.

Until today, CTI Start-up reviewed more than 1 800 projects, and awarded over 200 start-up enterprises with the CTI Start-up Label. Over 85% of these companies are still in business and some have shown remarkable growth, which is a sign that CTI Start-up guides them to sustainable success.

CTI also promotes the culture of entrepreneurship at universities, teaching hospitals, technical institutes as well as universities of applied sciences. CTI Entrepreneurship offers workshops to students on how to bring innovation to the market.

Website

ZKB Pionierpreis

Website

Neurimmune AG

Identification of novel therapeutics for the treatment of neurodegenerative disorders

Headquarter:
Schlieren

Foundation Date:
November 2006

Technology:

  • Biotech

Sectors:

  • Vaccines

Support received

  • Support venturelab
  • Support TOP 100